"Kungiyar SNIPR BIOME ta yi farin ciki game da wannan muhimmin ci gaba, kuma muna sa ran fara gwajin asibiti a Amurka daga baya a wannan shekara, muna gwada fasahar mu ta CRISPR ta musamman. SNIPR001 ita ce kadararmu mafi ci gaba, kuma muna alfahari da ƙoƙarin ƙungiyar da ta kawo mu nan,” in ji Dokta Christian Grøndahl, Co-kafa & Shugaba.
Gwajin gwaji na asibiti zai iya ba da hanya don sabon nau'in madaidaicin magani don zabar E. coli a cikin marasa lafiya na ciwon daji tare da cututtukan jini - wadanda suke da ciwon daji da ke shafar jini, kasusuwa, da ƙwayoyin lymph. Wadannan marasa lafiya suna cikin haɗarin kamuwa da cututtuka na jini na rayuwa saboda cutar, zuwa maganin chemotherapy da kuma, mahimmanci, zuwa fassarar pathogen daga gut, wanda E. coli yana daya daga cikin manyan 'yan wasan da ke haifar da kamuwa da cuta.
SNIPR001 yana da niyya don kai hari ga ƙwayoyin cuta na E. coli a cikin hanji, kuma ta haka ne ke hana jujjuyar waɗannan ƙwayoyin cuta zuwa jini, yayin da barin ƙwayoyin cuta masu alaƙa a cikin microbiome na majiyyaci ba su da tasiri. Hanya tare da SNIPR001 yana amfani da sabon aikace-aikacen fasaha na CRISPR/Cas na mallakarmu don zaɓar kawar da kwayoyin E. coli daga hanji. Wannan madaidaicin tsarin zai iya canza yadda ake hana kamuwa da cutar E. coli da kuma bi da su, musamman a sashen ciwon daji.
A yau, babu wasu hanyoyin da aka yarda da su don maganin rigakafi a cikin wannan saitin.
"Bisa ga bayanan da muka riga muka yi na asibiti tare da SNIPR001 mun yi imanin cewa fasaharmu tana da babbar dama wajen tsara magungunan CRISPR na gobe game da cututtuka masu barazana ga rayuwa da kuma daidaita cututtuka masu alaka da microbiome" in ji Dr. Milan Zdravkovic, Babban Jami'in Kiwon Lafiya da Shugaban R&D a SNIPR Biome. "Tare da haɓakar juriya na ƙwayoyin cuta akwai buƙatar gaggawa ga masu neman magani na novel don magance ƙwayoyin cuta, irin su E. coli, kuma muna godiya ga haɗin gwiwa tare da ƙungiyar masu zaman kansu, CARB-X akan SNIPR001".
SNIPR001 ita ce ta farko daga cikin 'yan takarar da za su iya warkewa da yawa, kamar yadda Dokta Christian Grøndahl ya bayyana: "Muna gina bututun bututun sabon kadarorin CRISPR kuma muna da fiye da sha'awar mu ga cututtuka masu yaduwa, haɗin gwiwa tare da MD Anderson Cancer Center kan rigakafi-oncology, kuma tare da Novo Nordisk akan amfani da fasahohin daidaita kwayoyin halitta akan microbiome. Muna farin cikin bincika cikakkiyar damar fasahar mu ta CRISPR a nan gaba ".
